Last reviewed · How we verify
Dixon up-and-down method
At a glance
| Generic name | Dixon up-and-down method |
|---|---|
| Sponsor | Yonsei University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- ED50 of Remimazolam for Anesthesia Induction in Frail Elderly Patients (NA)
- Minimum Effective Volume of Bupivacaine for Serratus Posterior Superior Intercostal Plane Block in Video-Assisted Thoracoscopic Surgery (NA)
- Impact of Frailty on Nalbuphine Dose for Postoperative Analgesia in Elderly Patients Undergoing Laparoscopic GI Surgery
- Optimal Concentration of Remifentanil for NIM Tube Intubation With Low-dose NMBA (NA)
- Esketamine and Propofol for Children With Autism Spectrum Disorder Undergoing Colonoscopy (NA)
- The Optimal Dosage of Ropivacaine for Arthroscopic Knee Surgery (EARLY_PHASE1)
- ED50 and ED95 of Intranasal Dexmedetomidine in Pediatric Patients Undergoing Transthoracic Echocardiography Study (PHASE4)
- A Sequential Allocation Study to Determine the ED50 of Dexmetedomidine as an Adjuvant to Lidocaine Intravenous Regional Anesthesia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dixon up-and-down method CI brief — competitive landscape report
- Dixon up-and-down method updates RSS · CI watch RSS
- Yonsei University portfolio CI